Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report.

COVID-19 Case reports Granulocyte and monocyte adsorptive apheresis Ulcerative colitis

Journal

Intestinal research
ISSN: 1598-9100
Titre abrégé: Intest Res
Pays: Korea (South)
ID NLM: 101572802

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 16 11 2020
accepted: 19 01 2021
pubmed: 28 4 2021
medline: 28 4 2021
entrez: 27 4 2021
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19.

Identifiants

pubmed: 33902268
pii: ir.2020.00148
doi: 10.5217/ir.2020.00148
pmc: PMC8831771
doi:

Types de publication

Case Reports

Langues

eng

Pagination

150-155

Références

Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
N Engl J Med. 1994 Jun 30;330(26):1841-5
pubmed: 8196726
Int J Colorectal Dis. 2011 Aug;26(8):999-1007
pubmed: 21476027
J Crohns Colitis. 2017 Jul 1;11(7):769-784
pubmed: 28513805
Clin Transl Gastroenterol. 2018 Jul 6;9(7):170
pubmed: 29977035
Ther Apher Dial. 2003 Feb;7(1):48-59
pubmed: 12921115
Digestion. 2021;102(5):814-822
pubmed: 32892197
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Crohns Colitis. 2020 Oct 21;14(14 Suppl 3):S791-S797
pubmed: 33085973
Int J Infect Dis. 2020 Oct;99:1-2
pubmed: 32721534
Dig Dis Sci. 2002 Jun;47(6):1334-41
pubmed: 12064810
Gastroenterology. 2008 Aug;135(2):400-9
pubmed: 18602921
Lancet Respir Med. 2020 Jun;8(6):e46-e47
pubmed: 32353251
Am J Gastroenterol. 2009 Dec;104(12):2990-5
pubmed: 19724269
Dig Liver Dis. 2014 Mar;46(3):219-26
pubmed: 24268950
Antibodies (Basel). 2020 Aug 15;9(3):
pubmed: 32824122
J Crohns Colitis. 2020 Oct 21;14(14 Suppl 3):S798-S806
pubmed: 32722754
J Crohns Colitis. 2017 Jan;11(1):84-91
pubmed: 27466171
J Gastroenterol. 2018 Mar;53(3):305-353
pubmed: 29429045

Auteurs

Miki Koroku (M)

Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.

Teppei Omori (T)

Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.

Harutaka Kambayashi (H)

Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.

Shun Murasugi (S)

Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.

Tomoko Kuriyama (T)

Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.

Yuichi Ikarashi (Y)

Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.

Maria Yonezawa (M)

Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.

Ken Arimura (K)

Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Kazunori Karasawa (K)

Division of Nephrology, Department of Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Norio Hanafusa (N)

Department of Blood Purification, Tokyo Women's Medical University, Tokyo, Japan.

Masatoshi Kawana (M)

Primary Care Center, Tokyo Women's Medical University, Tokyo, Japan.

Katsutoshi Tokushige (K)

Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.

Classifications MeSH